NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  CPI Card Group Inc. (“CPI” or the “Company”) (NASDAQ: PMTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CPI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 8, 2025, ...

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sensus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August ...

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Allegations - The investigation by Pomerantz LLP is focused on whether Nutex and its executives have engaged in securities fraud or other unlawful business practices [1]. - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which has been sued for a fraudulent scheme involving insurance companies [3]. Group 2: Market Reaction - Following the publication of the Blue Orca report, Nutex's stock price fell by $11.18 per share, representing a decline of 10.05%, closing at $100.01 per share on July 22, 2025 [4].

Core Viewpoint - Albany International Corp. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q2 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Albany reported non-GAAP earnings per share of $0.57 for Q2 2025, missing consensus estimates by $0.16 [3]. - The company's stock price fell by $16.77, or 23.63%, closing at $54.19 per share on July 31, 2025, following the earnings announcement [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Albany investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1].

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and stock price [1][3]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [3]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [3]. - Following the earnings announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Funko, Inc. and its officers or directors [1] Group 1: Company Developments - Funko announced the departure of its CEO, Cynthia Williams, effective July 5, 2025, which led to a significant stock price decline of $0.51 per share, or 10.49%, closing at $4.35 per share on July 7, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Group 1: Company Developments - On May 28, 2025, NWTN disclosed that it received a determination notice from Nasdaq, indicating that its securities would be delisted in accordance with listing rules [2] - Following this announcement, NWTN's stock price dropped by $0.72 per share, representing a 32% decline, closing at $1.53 per share on May 30, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NWTN Inc. and its officers or directors [1] Group 1: Company Developments - On May 28, 2025, NWTN disclosed that it received a determination notice from Nasdaq regarding the delisting of its securities [3] - Following the delisting news, NWTN's stock price dropped by $0.72 per share, representing a 32% decline, closing at $1.53 per share on May 30, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Viewpoint - Krispy Kreme, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in revenue and the suspension of its full-year guidance and dividend payments [1][3]. Financial Performance - On May 8, 2025, Krispy Kreme reported a notable decline in revenue attributed to "consumer softness leading to a decline in doughnut shop transaction volume" [3]. - The company pulled its full-year guidance and suspended future dividend payments due to a challenging environment and efforts to preserve cash [3]. Stock Market Reaction - Following the financial results announcement on May 8, 2025, Krispy Kreme's stock price fell by $1.07 per share, or 24.71%, closing at $3.26 per share [4]. - On May 9, 2025, after analysts from Evercore ISI and Citigroup reduced their price targets for Krispy Kreme, the stock price further declined by $0.53 per share, or 16.26%, closing at $2.73 per share [4].